Abstract: Lung cancer is a malignant tumor associated with the highest morbidity and mortality worldwide. Although platinum-based doublet chemotherapy has moderately improved the efficacy in advanced non-small cell lung cancer (NSCLC), prognosis of patients with NSCLC remains poor. To further improve the survival of patients with NSCLC, effective maintenance therapy is essential. This study reviews the current status of advanced NSCLC maintenance therapy and discusses the clinical significance of maintenance therapy and the selection process of an individualized treatment plan.